Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) Shares Outstanding (Weighted Average) (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 80.51% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 80.51% increase, with the full-year FY2025 number at $2.4 million, up 80.51% from a year prior.
  • Shares Outstanding (Weighted Average) was $2.4 million for Q4 2025 at Ekso Bionics Holdings, up from $2.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $25.4 million in Q1 2025 to a low of $1.2 million in Q2 2024.
  • A 5-year average of $10.2 million and a median of $12.7 million in 2021 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 94.11% in 2021, then crashed 91.16% in 2024.
  • Ekso Bionics Holdings' Shares Outstanding (Weighted Average) stood at $12.2 million in 2021, then rose by 6.31% to $13.0 million in 2022, then grew by 8.57% to $14.1 million in 2023, then plummeted by 90.45% to $1.3 million in 2024, then soared by 80.51% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Shares Outstanding (Weighted Average) are $2.4 million (Q4 2025), $2.2 million (Q3 2025), and $2.2 million (Q2 2025).